Question 1

What is Q32 Bio developing?

Accepted Answer

Q32 Bio is developing drugs that target powerful regulators of both the innate and adaptive immune systems with the goal of re-balancing the immune system.

Question 2

What is the company's most advanced product candidate?

Accepted Answer

Q32 Bio's most advanced product candidate is bempikibart, a fully human anti-interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody (mAb) designed to re-regulate adaptive immune function by blocking IL-7 and thymic stromal lymphopoietin (TSLP) signaling.

Question 3

What is the current status of bempikibart?

Accepted Answer

Bempikibart is currently being evaluated in two double-blind, placebo-controlled phase 2 studies: one in patients with atopic dermatitis (AD) and another in patients with alopecia areata (AA).

Question 4

What is ADX-097, the lead product candidate from Q32 Bio's tissue-targeted complement inhibitor platform?

Accepted Answer

ADX-097 is a humanized anti-C3d mAb fusion protein designed to restore complement regulation, which is an integral part of the innate immune system.

Question 5

What kind of team does Q32 Bio have?

Accepted Answer

Q32 Bio is comprised of an experienced and high-performing team of industry professionals, including talented scientists, immunologists, and drug developers, who are empowered to deliver on the company's mission.

Q32 Bio

Company Overview

Company Name

Address

Website

Phone

About Q32 Bio

More Companies in Massachusetts

Frequently Asked Questions about Q32 Bio

What is Q32 Bio developing?

What is the company's most advanced product candidate?

What is the current status of bempikibart?

What is ADX-097, the lead product candidate from Q32 Bio's tissue-targeted complement inhibitor platform?

What kind of team does Q32 Bio have?

Technologies Used

Social Profiles

Key Decision Makers